Inhibition of VEGFR2 using the monoclonal antibody ramucirumab (Cyramza®, LY3009806) significantly blunted cord formation promoted by either tumor cell lines or VEGF-A, as measured by a significant reduction in total tube area (≥65%) with treatment compared to controls (Figure 2). This evidence concerns the gene KDR and neoplasm.